Researchers Investigate New Treatment for Diabetes to Combat Sight Loss
Researchers at the University of Aberdeen are investigating a new treatment for diabetes which they hope could reduce one of the most common complications of the condition – sight loss.
The team of scientists are aiming to find new ways of preventing diabetic retinopathy (DR). The project is being led by Professor Mirela Delibegovic, with clinical colleagues Professor John Forrester and Dr Lucia Kuffova.
People living with cardiovascular disease and high blood pressure can develop a condition called retinal microvascular disease and this is increased in the presence of diabetes.
Diabetic retinopathy is one of the most common complications of diabetes. Those with DR develop damage, often permanent, to the retina – the light-sensing layer inside the eyeball – and as a result, are at risk of losing their sight.
Hope for the future
People in the UK known to have diabetes are offered retinal screening once a year to detect signs of changes in the retina caused by DR.
This new project aims to identify physical signs of DR when they occur, but before they lead to loss of vision, and to help find treatments to prevent it from developing.
Professor Delibegovic, who is the Director of the Aberdeen Cardiovascular Disease Centre at the University of Aberdeen, explains: “Given its nature, DR is a significant and worrying complication of diabetes and so it is important that we understand more about it and find ways to reduce and prevent it. In addition, as Type 2 diabetes – the most common type of diabetes – can often go undetected and undiagnosed for many years, up to 40% of people with Type 2 diabetes already have signs of DR when they are first diagnosed with the condition. Being able to intervene sooner could make a real difference for people living with diabetes.”
Over the next 3 years, the team will investigate if inhibition of an enzyme, called PTP1B, will lead to protection against retinal microvascular disease and diabetic retinopathy.
The project is one of 110 currently funded by BHF in ten universities across Scotland.
Head of BHF Scotland, James Jopling, said: “This is an important project which could benefit patients living with heart and circulatory disease and diabetes. As such, it is vital we understand more about diabetic retinopathy. Research projects like this one in Aberdeen help inform how we treat patients, identify those at particular risk and ultimately find new ways to save and improve lives.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more